O.RowleyJ
This reluctance is likely to be at least partially attributable to the fact that, until recently, all GLP-1RAs were available as subcutaneous (s.c.) injections, given twice daily (exenatide [13]), once daily (lixisenatide [14] and liraglutide [15]), or once weekly (semaglutide [16], dulaglutide [17], and exenatide extended release [18]), a route that may be less preferable to some patients compared with oral administration [1, 19]
The key is curation: a thoughtfully presented lobby, succinct categories, and reliable search tools reduce friction, conserve time, and let you assess volatility, return-to-player ranges, and bonus mechanics with confidence
Responsiveness to intervention: The good news is that visceral fat often responds more readily to weight loss than subcutaneous fat
doi: 10.1016/s1368-8375(02)00008-8
Background: The Rise and Regulation of Compounded GLP-1 Drugs To appreciate the significance of the FDAs latest action, some context is necessary